Intended for healthcare professionals


GSK will resume paying doctors to promote its drugs after policy U turn

BMJ 2018; 363 doi: (Published 03 October 2018) Cite this as: BMJ 2018;363:k4157
  1. Jacqui Wise
  1. London

The pharmaceutical giant GlaxoSmithKline (GSK) has announced that it will once again pay doctors to speak on its behalf about its drugs and associated diseases.

The UK based company announced at the end of 2013 that it would stop paying key opinion leaders and instead would rely more on its own clinical experts.1 That move came amid a major bribery investigation in China, which resulted in a record fine, and was an attempt to improve the company’s reputation.23 …

View Full Text

Log in

Log in through your institution


* For online subscription